Continuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation
Open Access
- 11 February 2021
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-14
Abstract
Multiple animal and human studies have shown that administration of GLP-1RA can enhance β-cell recovery, reduce insulin dosage, reduce HbA1c content in the blood, reduce the risk of hypoglycemia and reduce inflammation. In the NOD mouse model, peptide VP treatment can prevent and treat type 1 diabetes through immunomodulation. Therefore, we designed a new dual-functional PGLP-1-VP, which is expected to combine the anti-inflammatory effect of PGLP-1 and the immunomodulatory effect of VP peptide. In streptozotocin-induced hyperglycemic mice model, we demonstrated that PGLP-1-VP can act as a GLP-1R agonist to improve hyperglycemia and increase insulin sensitivity. In the NOD mouse model, PGLP-1-VP treatment reduced morbidity, mortality, and pancreatic inflammation, and showed superior effect to PGLP-1 or VP treatment alone, confirming that PGLP-1-VP may act as a dual-function peptide. PGLP-1-VP provided immunomodulatory effect through increasing Th2 cell percentage and balancing the ratio of Th2/Th1 in spleen and PLN, similar to P277 and VP. Additionally, PGLP-1-VP and PGLP-1 act the anti-inflammation by increasing Treg cells and TGF-β1 content like DPP-IV inhibitor. Taken together, our data shows that the dual-functional PGLP-1-VP reduces morbidity and mortality in the NOD model, suggesting a potential role in preventing and treating type 1 diabetes.Keywords
Funding Information
- National Natural Science Foundation of China (81570696)
- Excellent Youth Foundation of Jiangsu Scientific Committee (BK20140029)
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- Pingdingshan High-level Talent Startup Fund (PXY-BSQD-2018011)
- Key research projects of Henan higher education institutions (20B350006)
- Henan Provincial Key Science and Technology Research Projects (202102310478)
This publication has 66 references indexed in Scilit:
- Improved Metabolic Control in Diabetes, HSP60, and Proinflammatory MediatorsAutoimmune Diseases, 2012
- Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfactionPrimary Care Diabetes, 2012
- Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β-Cell FunctionDiabetes Care, 2011
- How Punctual Ablation of Regulatory T Cells Unleashes an Autoimmune Lesion within the Pancreatic IsletsImmunity, 2009
- Inhibition of Th17 Cells Regulates Autoimmune Diabetes in NOD MiceDiabetes, 2009
- Dipeptidyl Peptidase IV Inhibition With MK0431 Improves Islet Graft Survival in Diabetic NOD Mice Partially via T-Cell ModulationDiabetes, 2009
- Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector categoryJournal of Experimental Medicine, 2008
- Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic miceNature Immunology, 2005
- THE NOD MOUSE: A Model of Immune DysregulationAnnual Review of Immunology, 2005
- Imbalance in Th Cell Polarization and its Relevance in Type 1 Diabetes MellitusThe Review of Diabetic Studies, 2005